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The sirtuins (SIRTs) are protein-modifying enzymes that are distributed ubiquitously in all or-
ganisms. SIRT1 is a mammalian homologue of yeast nicotinamide-adenine-dinucleotide-de-
pendent deacetylase silent information regulator 2 (known as Sir2), which is the best-charac-
terized SIRT family member. It regulates longevity in several model organisms and is involved 
in several processes in mammalian cells including cell survival, differentiation, and metabo-
lism. SIRT1 induction, either by SIRT-activating compounds such as resveratrol, or metabolic 
conditioning associated with caloric restriction, could have neuroprotective qualities and thus 
delay the neurodegenerative process, thereby promoting longevity. However, the precise me-
chanistic liaison between the activation of SIRT and extended healthy aging or delaying age-
related diseases in humans has yet to be established. 
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Introduction 
 
Neurodegenerative disorders including Huntington’s disease, 
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), 
and Alzheimer’s disease (AD) are characterized by irreversi-
bility, a progressive clinical course, and idiopathic degener-
ation of specific selectively vulnerable neuronal populations. 
These debilitating neurodegenerative diseases are inherently 
associated with the accumulation of misfolded proteins that 
adversely affect neuronal connectivity and plasticity, and trig-
ger cell-death-signaling pathways.
1 However, the precise se-
quence of the events that underlie disease progression remains 
to be identified, and this largely explains the absence of me-
thods and effective therapeutic interventions for this group of 
diseases. While the misfolded proteins typically exhibit loss 
of function, mislocalization, and tendency toward aggrega-
tion, most of these processes are strongly influenced by aging, 
which is the predominant and unifying risk factor for neuro-
degenerative diseases. 
It is well established that low-calorie diets, known as “calo-
ric restriction” (CR), extend lifespan in a wide variety of or-
ganisms including yeast, Caenorhabditis elegans, Drosophila 
species, and rodents, and it has been proposed that the sir-
tuins (SIRTs) might at least partly mediate this effect.
2 Thus, 
activating molecular pathways that slow the process of aging 
may provide an outstanding strategy for treating and prevent-
ing these conditions. This is where SIRTs may come into play, 
which are nicotinamide adenine dinucleotide (NAD
+)-depen-
dent enzymes that have emerged as important regulators of 
diverse biological processes and are referred to as either SIRTs 
or silent information regulator 2 (Sir2)-like proteins. They con-
stitute the class III histone deacetylases and are conserved 
from bacteria to humans.
3 The founding member, yeast Sir2 
(ySir2), is essential for maintaining silent chromatin through 
the deacetylation of histones. Since the discovery of the invol-
vement of SIRT in apoptosis, cell survival, transcription, meta-
bolism, and aging, these activities have been implicated as dis-
ease modifiers. This review highlights the role of SIRTs as po-
tential therapeutic targets for developing treatments for neuro-
degenerative disorders. Although SIRT1 and SIRT2 play im-
portant roles in aging and neurodegeneration, very little is 
known about their role in the central nervous system (CNS). 
Therefore, following a brief description of the SIRTs in gen-
eral, this review focuses on SIR1 and SIR2.  
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The Sirtuins 
 
SIRTs, a family of NAD
+-dependent deacetylases and/or ad-
enosine diphosphate (ADP)-ribosyltransferases, are an evo-
lutionarily conserved class of proteins that regulate various 
cellular functions such as genome maintenance, longevity, 
metabolism, and tolerance to oxidative stress.
4-6 These enzy-
mes were first identified in yeast as silent information regu-
lators, hence the family name.
7 SIRTs regulate cell functions 
by deacetylating both histone and nonhistone targets. Sir2 in 
Saccharomyces cerevisiae is the founding member of the 
SIRT gene family, and its deacetylase activity is required for 
chromatin silencing at the mating-type loci, telomeres, and 
the ribosomal DNA locus. Seven distinct Sir2 homologues 
have been identified in humans (SIRT1-SIRT7), each having 
distinct cellular targets and diverse cellular localizations. Ro-
bust protein deacetylase activity has been reported for SIRT1, 
SIRT2, SIRT3, and SIRT5, whereas SIRT4, SIRT6, and SIRT7 
have no detectable enzymatic activity on a histone peptide 
substrate.
8 The current consensus suggests that mammalian 
SIRTs comprise two nuclear (SIRT1, SIRT6), one cytoplasmic 
(SIRT2), three mitochondrial (SIRT3, SIRT4, and SIRT5), 
and one nucleolar (SIRT7) protein (Table 1).
9 
 
Sirtuin 1 
 
SIRT1, which is found predominantly in the nucleus, has the 
highest sequence homology to ySir2. An early insight into 
one mechanism whereby Sir2 could increase the replicative 
lifespan of yeast comes from the discovery that it acts at the 
nucleolus, inhibiting ribosomal DNA (rDNA) recombination 
as well as extrachromosomal rDNA circle formation.
10 It is the 
best-investigated and most-well-understood member of the 
human family of SIRTs in terms of its endogenous function 
and activity, and is suggested to play an essential role in life-
span extension (on CR), the oxidative stress response [poly 
(ADP-ribose) polyMerase], and regulation of forkhead trans-
cription factors (FOXOs) and p53. Other important subst-
rates of SIRT1 include, Ku70, peroxisome proliferator-acti-
vated receptor-γ coactivator-1α (PGC-1α), liver X receptor 
(LXR), and histones H1, H3, and H4, with histone deacety-
lation causing gene silencing.
11 SIRT1 physically interacts 
with p53 in the nucleus, an interaction that is enhanced after 
the induction of DNA damage. Acetylation of p53 results in 
the activation of p53 target genes such as p21, resulting in 
cell-cycle arrest, apoptosis, or senescence. Conversely, dea-
cetylation of p53 by SIRT1 decreases p53-mediated trans-
criptional activation.
12 SIRT1 activity results in the suppress-
ion of apoptosis induced by DNA damage or oxidative stress 
(Fig. 1). 
Since nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-κB) exerts an antiapoptotic effect during 
tumor necrosis factor-α (TNF-α) activation, inhibition of NF-
κB-mediated gene activation by SIRT1 sensitizes cells to ap-
optosis during TNF-α treatment. Ku70 is a subunit of the Ku 
protein complex, which is involved in the nonhomologous 
repair of DNA double-strand breaks. SIRT1 and Ku70 phy-
sically interact in vivo, and overexpression of SIRT1 de-
creases the acetylation level of Ku70, thereby promoting the 
antiapoptotic Bcl-2-associated X protein-Ku70 interaction. 
Members of the FOXO family of transcription factors are 
involved in cellular processes that range from longevity, me-
Table 1. Mammalian SIRTs: subcellular localization, putative targets, putative functions, and potential links with disease 
SIRT 
Subcellular 
localization 
Putative targets 
Therapeutic 
strategies 
Putative function  Potential link with diseases 
SIRT1 Nucleus  p53,  Ku70,  PPAR-γ, 
PGC-1α, NF-κB, 
p300, FOXO 
Activation  Regulation of cell survival 
 and  metabolism, 
 stress  response  control 
Aging, obesity, insulin 
 resistance,  inflammation, 
  diabetes, heart failure, 
  axonal degeneration, AIDS 
SIRT2 Cytoplasm/Nucleus  α-tubulin, histone H4  Inhibition/ 
Activation? 
Regulation of microtubule 
 stability,  heterochromatin 
 formation,  cell-cycle 
 regulation 
Down-regulated in 
 human  gliomas 
SIRT3 Mitochondria  AceCS2,  PGC-1α  Activation  Activation of mitochondrial 
  function, regulation of 
 thermogenesis 
Adaptive thermogenesis, 
  overexpressed in node- 
positive breast cancer 
SIRT4 Mitochondria  Glutamate 
dehydrogenase 
Inhibition? Down-regulation  of  insulin 
  secretion in response to 
 amino  acids 
Inhibits amino-acid- 
stimulated insulin 
 secretion 
SIRT5 Mitochondria  Unknown Unknown  Unknown  Unknown 
SIRT6 Nucleus  (associated 
 with  heterochromatin) 
DNA polymerase β  Activation  DNA repair/Control, ADP- 
ribosyltransferase activity 
Age-related diseases 
SIRT7 nucleus  (concentrated 
 in  nucleoli) 
RNA polymerase I  Activation  Regulation of rRNA synthesis 
  and ribosome production 
Highly expressed in thyroid 
  cancers, overexpressed in 
  node-positive breast cancer 
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tabolism, and reproduction in C. elegans to the regulation of 
gene transcription downstream from insulin, cell-cycle arrest, 
apoptosis, and stress responses in mammalian cells, and acety-
lation, and function as transcriptional coactivators.
13,14 SIRT1 
interacts with FOXO proteins and deacetylates FOXO1, FO-
XO3, and FOXO4. It appears that SIRT1 shifts FOXO-me-
diated processes from induction of apoptosis to cell-cycle 
arrest and cellular survival. 
In mouse embryos, SIRT1 was expressed at high levels in 
the heart, brain, spinal cord, and dorsal root ganglia.
15 High 
SIRT1 levels in the embryonic brain suggest that it plays a 
role in neuronal and/or brain development. This notion is sup-
ported by some of the phenotypes associated with SIRT1-
knockout mice, in which postnatal survival is infrequent, and 
which have developmental defects such as exencephaly and 
retinal anomaly.
16 In the adult rat brain, SIRT1 can be found 
in the hippocampus, cerebellum, and cerebral cortex. The an-
tioxidant vitamin E has been shown to reduce the oxidative 
damage and reduction of SIRT1 caused by a high-fat and 
high-sugar diet, while restoring SIRT1 levels.
17  
The findings of that study suggest that SIRT1 levels in the 
brain are affected by oxidative stress and energy homeosta-
sis. There is also recent evidence that SIRT1 deacetylates au-
tophagy genes and stimulates basal rates of autophagy,
18 
which has emerged as an important route for the removal of 
the toxic misfolded protein aggregates that accumulate in 
neurodegenerative diseases. 
 
Sirtuin 2 
 
The human SIRT2 protein is a closer homologue to the yeast 
Hst2p than to ySir2. Both proteins are localized in the cyto-
plasmic compartment, but human SIRT2 is also localized al-
ong the microtubule network.
19 SIRT2 has been reported to 
promote neuronal death. Pharmacological and genetic inhibi-
tion of SIRT2 protects neurons against α-synuclein toxicity 
both in vitro and in flies.
20 In addition to deacetylating his-
tone-H3 peptide acetylated on lysine-14, SIRT2 is capable of 
deacetylating an acetylated α-tubulin peptide, an ability that 
Hst2p clearly lacks. Hence, SIRT2 shows a preference for an 
α-tubulin peptide over a histone peptide, suggesting that 
SIRT2 has evolved to carry out the deacetylation of tubulin. 
As tubulin acetylation is implicated in the regulation of cell 
shape, intracellular transport, cell motility, and cell division, 
it will be of future interest to address the role of SIRT2 in 
tubulin deacetylation, as well as in the concept of CNS dis-
eases. The SIRT2 gene is found at chromosome 19q13.2, a 
region that is frequently deleted in human gliomas. Further-
more, the ectopic expression of SIRT2 in a glioma cell line 
has been shown to decrease colony formation, suggesting a 
potential tumor-suppressor role for SIRT2. This could be ex-
plained by SIRT2 playing an important role in the control of 
mitotic exit in the cell cycle, where increased SIRT2 activity 
severely delays cell-cycle progression through mitosis.
21 SIRT2 
was very recently described as an oligodendroglial cytoplas-
mic protein localized to the outer and juxtanodal loops in the 
myelin sheath, and which decreases cell differentiation th-
rough α-tubulin deacetylation, suggesting a potential role in 
myelinogenesis.
22 
 
Neurodegenerative Diseases 
 
Many neurodegenerative disorders are characterized by con-
formational changes in proteins that result in misfolding, ag-
gregation, and intra- or extraneuronal accumulation of amy-
loid fibrils. The variety and complexity of these diseases are 
related to the different pathological conformations that the 
proteins involved can assume. Most conformational diseases, 
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Fig. 1. Convergence of stress signals on SIRT1,
an upstream regulator of multiple effectors of the
stress response. SIRT: sirtuin, NF-κB: nuclear fac-
tor kappa-lightchain-enhancer of activated B cells,
FOXO: forkhead transcription factor, LXR: liver
X receptor, PPAR: peroxisome proliferator-acti-
vated receptor, NBS: nigonegen breakage syn-
drome, BCL: B-cell lymphoma, PGC: PPAR gam-
ma coactivator.  
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such as AD, PD, and ALS, are caused by a combination of 
genetic and environmental factors, suggesting that spontane-
ous events can destabilize a misfolding-prone protein or im-
pair the clearance mechanisms, leading to the accumulation 
of misfolded aggregates. While aging is a major risk factor 
because it may compromise both the cellular processing and 
clearance systems, environmental factors affect the probabi-
lity of disease onset and progression. 
The currently available therapeutic strategies are still not 
effective enough to slow or prevent these diseases; the deve-
lopment of new therapeutic approaches that specifically tar-
get the pathogenic proteins is therefore mandatory. Below we 
describe some of the representative neurodegenerative disor-
ders that represent potential targets of SIRT-related mecha-
nisms. 
 
Alzheimer’s Disease 
 
The histopathological hallmarks of AD are the presence of 
intraneuronal neurofibrillary tangles and the accumulation of 
extracellular amyloid plaques in the brains of affected indi-
viduals. A link between SIRT1 and AD is also becoming in-
creasingly evident. NF-κB signaling in microglia is known 
to be critically involved in neuronal death induced by Aβ 
peptides.
23 
SIRT1 protects against Aβ-induced neurotoxicity by inhi-
biting NF-κB signaling in microglia. Overexpression of SIRT1 
and resveratrol treatment has been shown to markedly re-
duce Aβ-stimulated NF-κB signaling and to exert a strong 
neuroprotective effect. This finding concurs with the known 
role of SIRT1 in modulating NF-κB activity.
24 Shortterm CR 
was shown to substantially decrease the accumulation of Aβ 
plaques in two AD-prone amyloid precursor protein (APP)/ 
presenilin transgenic mouse lines, and to decrease gliosis, as 
marked by astrocytic activation. The authors suggest that CR 
enhances the clearance of brain Aβ by reducing brain insulin 
as a competing substrate. The overexpression of SIRT1 or 
pharmacological activation of SIRT1 by NAD
+ also promotes 
α-secretase activity and attenuates the generation of Aβ pep-
tides in embryonic Tg2576 mouse neurons in vitro. 
Moreover, in Tg2576 mice, CR resulted in a larger than 
twofold increase in the concentration of brain soluble APPα 
(a product of α-secretase cleavage of APP) and a statistically 
significant 30% increase in ADAM10 (A Disintegrin And 
Metallopeptidase 10, a putative α-secretase) levels in CR ani-
mals compared to controls.
25 Other mechanisms could in-
clude lower cholesterol and higher glucocorticoid levels in 
CR mice.
26 In a recent investigation using resveratrol, which 
is a well-known CR-mimicking agent, we found that Aβ-in-
duced neurodegeneration was attenuated by the mechanisms 
involved in the 5’ adenosine monophosphate-activated pro-
tein kinase (AMPK) pathways (unpublished data). It is thus 
possible that SIRT regulates one or more of the AMPK ki-
nases.
27 Another plausible explanation is the activation of 
SIRT1 by CR. 
 
Parkinson’s Disease 
 
PD is characterized neuropathologically by the selective and 
progressive degeneration of dopaminergic neurons in the sub-
stantia nigra pars compacta, which is accompanied by mus-
cle rigidity, bradykinesia, resting tremor, and postural insta-
bility. There is a growing body of evidence that both genetic 
and environmental factors contribute to the acceleration of 
dopaminergic neurodegeneration in this neurological disor-
der. In particular, mitochondrial dysfunction has been consi-
dered one of the most important factors involved in the pa-
thogenesis of PD. While misfolding, oligomerization, and ag-
gregation of α-synuclein have been implicated in PD patho-
logy, the precise mechanisms underlying the neurodegener-
ation remains to be determined. 
Okawara et al.
21 recently investigated whether resveratrol 
exhibits neuroprotective effects on dopaminergic neurons in 
organotypic midbrain slice cultures subjected to several dif-
ferent types of insult related to PD pathogenesis. They de-
monstrated that resveratrol, together with another SIRT-acti-
vating compound, quercetin, prevents the decrease of dopa-
minergic neurons induced by a dopaminergic neurotoxin 1-
methyl-4-phenyl pyridinium. They suggested that resveratrol 
exerts neuroprotective effects in dopaminergic neurons via 
either antioxidative or SIRT-activating activity. Moreover, Ou-
teiro et al.
28 recently described the identification and charac-
terization of SIRT2 inhibitors and demonstrated that pharma-
cological and genetic inhibition of SIRT2 rescues cell cul-
tures from α-synuclein toxicity. However, it is still unclear 
whether it is the antioxidant or SIRT-activating activity (or 
both) that underlies this neuroprotective effect of resveratrol. 
 
Amyotrophic Lateral Sclerosis 
 
ALS is an adult-onset neurodegenerative disease characteriz-
ed by the selective vulnerability of motor neurons in the sp-
inal cord, brainstem, and motor cortex, causing progressive 
muscle weakness, atrophy, paralysis, and bulbar dysfunction, 
and leads to death within 3-5 years of disease onset in most 
cases. The sporadic form of the disease, which accounts for 
90% of cases, remains poorly understood. The pathogenesis 
of ALS is not fully understood in the vast majority of cases, 
and the mechanisms involved in motor neuron degeneration 
are multifactorial and complex. There is substantial evidence  
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to support the hypothesis that oxidative stress can underlie 
motor neuron death.
29 Mitochondrial dysfunction and neuro-
inflammation have also been implicated in ALS pathogene-
sis. Peroxisome proliferator-activated receptors (PPARs), and 
in particular PPAR-γ, may form part of a major signaling pa-
thway involved in neuroinflammation in ALS.
30 The activa-
tion or inactivation of PPAR-γ could provide a viable and 
promising approach to understanding the mechanism of neu-
roinflammation in ALS. SIRT1 physically interacts with and 
deacetylates PPAR-γ, coactivator-1α  (PGC-1α) at multiple 
lysine sites, consequently increasing PGC-1α activity. These 
findings suggest that PPAR-γ is an important regulator of 
neuroinflammation, and a new potential target for the deve-
lopment of therapeutic strategies for ALS.
31 
More recent studies have demonstrated that SIRT1 is pro-
tective in vitro against the cytotoxic effects of a mutant supe-
roxide dismutase 1 that causes familial ALS.
32 
 
Concluding Remarks 
 
It has been demonstrated that CR is one of the most effective 
means of slowing the pace of aging and extending lifespan in 
many organisms, from yeast to mammals. In yeast, the lon-
gevity gene induced by CR is Sir2. In mammals, SIRT1, an 
ortholog of Sir2, controls the metabolism of white adipose 
tissue. Resveratrol, a polyphenolic compound obtained from 
grapes and red wine, is the most potent natural product acti-
vator of SIRT1. Originally identified through the recognition 
of the French paradox (a phenomenon whereby individuals 
with high-fat diets have a low incidence of cardiovascular 
disease due to the regular consumption of red wine), resvera-
trol has demonstrated therapeutic efficacies in models of car-
diovascular, metabolic, inflammatory, and neurodegenerative 
diseases, and has shown chemopreventative activity.
33 A full 
understanding of the effects of SIRT manipulation in mam-
mals necessitates the design and generation of additional tr-
ansgenic and knockout mice to facilitate further investiga-
tions into SIRT biology. These models will be critical to 
elucidating the relationship between SIRTs, metabolism, and 
aging. SIRT-based therapies (i.e., small-molecule SIRT acti-
vators) hold great promise as potential therapeutic modalities 
for age-related conditions, and especially for neurodegener-
ative diseases. 
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